{"organizations": [], "uuid": "edc41c6a3e9a3dadf78821696832fd125cba94f6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/vertex-pharms-study/vertex-pharmas-quarterly-profit-falls-15-1-percent-idUSL3N1S37HE", "country": "US", "domain_rank": 408, "title": "Vertex Pharma's quarterly profit falls 15.1 percent", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T23:13:00.000+03:00", "replies_count": 0, "uuid": "edc41c6a3e9a3dadf78821696832fd125cba94f6"}, "author": "", "url": "https://www.reuters.com/article/vertex-pharms-study/vertex-pharmas-quarterly-profit-falls-15-1-percent-idUSL3N1S37HE", "ord_in_thread": 0, "title": "Vertex Pharma's quarterly profit falls 15.1 percent", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "sai sachin ravikumar", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "vertex pharma", "sentiment": "negative"}, {"name": "vertex", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "vertex pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Corrects to say revenue fell, not rose, in paragraph 3)\nApril 26 (Reuters) - Vertex Pharmaceuticals Incâ€™s quarterly profit fell 15.1 percent, hurt by higher research and development spending.\nVertex said on Thursday income attributable to the company fell to $210.3 million or 81 cents per share in the three months ended March 31, from $247.8 million or 99 cents per share, a year earlier.\nVertex, one of the top U.S. manufacturers of treatments for lung disorder cystic fibrosis, said its revenue fell to $640.8 million from $714.7 million.\nThe company also separately said it had begun a late-stage study of a triple combination treatment for cystic fibrosis. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)\n ", "external_links": [], "published": "2018-04-26T23:13:00.000+03:00", "crawled": "2018-04-26T23:34:41.021+03:00", "highlightTitle": ""}